Drug Profile

Guselkumab biosimilar - Polpharma Biologics

Alternative Names: PB-019

Latest Information Update: 08 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Polpharma Biologics
Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Urologics
Mechanism of Action Interleukin-23 subunit p19 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Plaque psoriasis; Psoriatic arthritis

Most Recent Events

02 Sep 2025 Guselkumab biosimilar licensed to MS Pharma in Middle East & North Africa
02 Sep 2025 Preclinical trials in Plaque psoriasis in Poland (Parenteral), before September 2025
02 Sep 2025 Preclinical trials in Psoriatic arthritis in Poland (Parenteral), before September 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com